Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Stains remain the first therapeutic approach in patients with dyslipidemia to control plasma lipids levels and cardiovascular risk. Multiple clinical trials have demonstrated the benefits of statins in reducing major cardiovascular adverse events in primary and secondary prevention. Moreover, in patients with coronary artery disease, statins decrease coronary atherosclerotic plaque volume and composition, inducing atheroma stabilization. Pitavastatin, is a new-generation lipophilic statin, indicated for the treatment of dyslipidemia and prevention of cardiovascular diseases. The purpose of this review, the first at our knowledge on this topic, is to summarize and examine the current knowledge about the effectiveness of pitavastatin in patients with coronary artery disease. The available data suggest that pitavastatin significantly, lowers the rate of adverse cardiovascular events, in patients at a high risk of atherosclerotic disease, with stable angina pectoris or with acute coronary syndrome. Moreover intravascular ultrasound have shown that pitavastatin induces favorable changes in plaque morphology, increasing the fibrous cap thickness, and decreasing both plaque and lipid volume indexes. Globally the efficacy of pitavastatin is greater or similar to other statins. © 2022. Italian Society of Hypertension.


Francesco Fici, Gokhan Faikoglu, Bahar Arican Tarim, Nicolas Roberto Robles, Kostas Tsioufis, Guido Grassi, Barış Gungor. Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension. 2022 Mar;29(2):137-144

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 35064911

View Full Text